Codexis, Inc.

Applied Molecular Transport Inc.

Sally Rhiannon Postlethwaite

Randall J Mrsny

Tahir Mahmood

Weijun Feng

Louis Clark

Charles Olson

Jie Yang

Xiyun Zhang

Lisa Marie Newman

Dipnath Baidyaroy

Attila Andor

Catherine M Cho

Sean Dalziel

John Joseph Koleng, Jr

Derek Maclean

Marvin R Garovoy

Thomas Carl Hunter

Rajendra Tandale

Hyojin Kim

Bittoo Kanwar

Kevin Yin

Khushdeep Mangat

Amir Porat

Ish Kumar Dhawan

Kripa Rao

The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Cholix-derived carriers for oral delivery of heterologous payload

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Compositions, formulations and interleukin production and purification

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in theof the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.

Delivery constructs for transcytosis and related methods

The invention relates to recombinantly produced &#x3b2;-glucosidase variants with enhanced thermoactivity compared to naturally occurring proteins. The invention also provides methods for producing a variant &#x3b2;-glucosidase polypeptide with improved thermoactivity by identifying performance sensitive positions in a target &#x3b2;-glucosidase polypeptide and substituting the residue at that position with a thermoactivity enhancing residue.

Beta-glucosidase variants

&#x3b2;-glucosidase variants

The invention relates to a multi-cellulase enzyme composition for the enzymatic hydrolysis of cellulosic biomass said composition comprising a cellobiohydrolase (CBH) enzyme, an endoglucanase (EG) enzyme and a &#x3b2;-glucosidase (BG) enzyme.

Multi-cellulase enzyme compositions for hydrolysis of cellulosic biomass

The invention relates to recombinantly produced &#x3b2;-Glucosidase Variants with enhanced thermoactivity compared to naturally occurring proteins. The invention also provides methods for producing a variant &#x3b2;-glucosidase polypeptide with improved thermoactivity by identifying performance sensitive positions in a target &#x3b2;-glucosidase polypeptide and substituting the residue at that position with a thermoactivity enhancing residue.

&#x3b2;-Glucosidase variants

The invention provides variants of theCelA &#x3b2;-glucosidase that have improve &#x3b2;-glucosidase activity, particularly improved thermoactivity, compared to the wild type enzyme. The invention further provides related polynucleotides, vectors, host cell, and methods for making and using the variants.

Method for producing an alcohol using &#x3b2;-glucosidase variant enzymes

Method of converting a biomass substrate to a fermentable sugar using a beta-glucosidase variant enzyme

Beta-glucosidase variant enzymes and related polynucleotides

Growing community of inventors

Redwood City, CA, United States of America

Sally Rhiannon Postlethwaite